There is a newer version of this record available.

Working paper Open Access

Ivermectin for Covid-19

Sparavigna, Amelia Carolina


Citation Style Language JSON Export

{
  "publisher": "Zenodo", 
  "DOI": "10.5281/zenodo.3922298", 
  "language": "eng", 
  "title": "Ivermectin for Covid-19", 
  "issued": {
    "date-parts": [
      [
        2020, 
        6, 
        29
      ]
    ]
  }, 
  "abstract": "<p>Discussion of scholar papers published until June 29, 2020,&nbsp; on Ivermectin, and of news that we can find about its use for Covid-19.&nbsp; A list of clinical trials is also given. For what concerns scholar papers, we report among them a preprint posted on 10 June in MedR&chi;iv,&nbsp; which concludes that Ivermectin was associated with lower mortality during treatment of Covid-19.&nbsp; From news, we consider in particular the case of Iquitos,&nbsp; capital city of the Loreto Region in Peru, where, by May 25, Covid-19 cases and deaths had dropped notably. The formulation of ivermectin used in Peru is also discussed, in particular that of the oral solution disclosed by the Peruvian Government.</p>", 
  "author": [
    {
      "family": "Sparavigna, Amelia Carolina"
    }
  ], 
  "type": "article", 
  "id": "3922298"
}
2,121
890
views
downloads
All versions This version
Views 2,121271
Downloads 890126
Data volume 189.8 MB31.4 MB
Unique views 1,785222
Unique downloads 746111

Share

Cite as